Ig Vena

Human Normal Immunoglobulin, the active ingredient in Ig Vena, is an immunoglobulin presented as an intravenous solution for intravenous use. It provides passive immunity and is used to replace deficient antibodies in patients with primary or secondary immunodeficiency, Kawasaki disease, and refractory immune thrombocytopenic purpura. GNH USA supplies Ig Vena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ig Vena, a human normal immunoglobulin, is used in conditions where antibody deficiency or immune dysregulation occurs.

- Primary immunodeficiency diseases: restores missing IgG antibodies to reduce infection risk. - Secondary immunodeficiency (e.g., chemotherapy, HIV): supplements depleted immunoglobulins to support immune function. - Kawasaki disease: reduces inflammation and coronary artery complications in the acute phase. - Immune thrombocytopenic purpura (refractory ITP): provides immunomodulation to increase platelet counts when other therapies fail.

Common Side Effects: - Headache: mild to moderate, often transient. - Fever and chills: usually occur during or shortly after infusion. - Fatigue or malaise: may last several hours post‑infusion. - Nausea or vomiting: generally mild and self‑limiting. - Arthralgia or myalgia: joint and muscle aches during treatment.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Aseptic meningitis: rare neurological complication presenting with headache and neck stiffness. - Thromboembolic events: clot formation in veins or arteries, especially with rapid infusion. - Renal failure: acute kidney injury, particularly in patients with pre‑existing renal risk. - Hemolytic anemia: immune‑mediated destruction of red blood cells. - Severe infusion reactions: hypotension, dyspnea, or cardiac arrhythmias.

Ig Vena should be administered with careful clinical assessment and monitoring.

- Assess IgA deficiency: test for anti‑IgA antibodies before infusion to avoid anaphylaxis. - Monitor renal function: avoid high infusion rates in patients with renal impairment. - Evaluate thrombotic risk: use caution in patients with cardiovascular disease or hypercoagulable states. - Adjust infusion rate: start slowly and increase gradually if tolerated to reduce adverse reactions. - Pregnancy and lactation: use only if the expected benefit justifies potential risk; data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ig Vena may interact with several medications and vaccines.

Major Interactions (Avoid): - Live attenuated vaccines: concurrent use may reduce vaccine efficacy; schedule separately. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect; monitor INR closely.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., rituximab): may affect therapeutic response. - Corticosteroids: combined use can increase infection risk. - Diuretics: may raise the likelihood of renal dysfunction. - Inactivated vaccines: generally safe but monitor immune response. - Other blood products: consider timing to avoid interference with immunoglobulin levels.